Trials
8 active
18 in total · 9 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Depemokimab as a sterile liquid formulation will be administered.”In the company’s words, NCT06961214 on ClinicalTrials.gov
- Tested for
- Asthma (3 trials), Pulmonary Disease, Chronic Obstructive (3 trials), Nasal Polyps, Hypereosinophilic Syndrome
- Main trialPhase 4
- “This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).”In the company’s words, NCT07701967 on ClinicalTrials.gov
- Other names
- GSK3511294
Other drugs for Asthma
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
Coming up8
- 1 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2027Phase 4 trial completes · ClinicalTrials.gov
- 29 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 5 Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- 13 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 13 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 2 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
- 23 Sep 2030Phase 3 trial completes · ClinicalTrials.gov
Changes3
Last 90 days- 18 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT05263934
- 18 NovCompletion date moved: 2026-09-29 to 2026-10-06 · ClinicalTrials.gov NCT05263934
- 17 NovCompletion date moved: 2029-04-30 to 2029-04-02 · ClinicalTrials.gov NCT07177339
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 28 Jun 2027 | Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | |
| Phase 3Recruiting | 1 Mar 2027 | A Study of Depemokimab in Participants of 6 to 11 Years of Age | |
| Phase 3Active, not recruiting | 29 Oct 2027 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | |
| Phase 3Recruiting | 5 Jan 2028 | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | |
| Phase 3Recruiting | 13 Dec 2028 | Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | |
| Phase 3Recruiting | 13 Dec 2028 | Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation | |
| Phase 3Recruiting | 2 Apr 2029 | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | |
| Phase 3Recruiting | 23 Sep 2030 | A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma | |
| Phase 3Completed | 21 Nov 2023 | Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | |
| Phase 3Completed | 11 Apr 2024 | A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | |
| Phase 3Completed | 12 Jul 2024 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) | |
| Phase 3Completed | 30 Jul 2024 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps | |
| Phase 3Completed | 19 May 2025 | An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) | |
| Phase 3Completed | 14 Sep 2025 | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype | |
| Phase 3Completed | 6 Oct 2026 | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | |
| Phase 1Completed | 31 Jul 2019 | First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma | |
| Phase 1Completed | 23 Dec 2022 | Study of GSK3511294 in Healthy Chinese Participants | |
| Phase 1Completed | 23 Oct 2023 | A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026